Summary:
A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed. If the original donor is not available, a different donor may have to be considered. We report our experience of performing a second allogeneic HSCT using a different donor in patients with relapsed leukemia and lymphoma. In a 5-year period, six patients underwent a second allograft with myeloablative conditioning using a different donor. Four of these were retransplanted using a matched-unrelated donor. Four of the patients (67%) remain progression-free at a median follow-up of 32 months (range 3–72). There were no cases of transplant-related mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kumar L . Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710–1717.
Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.
Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50–57.
Bosi A, Laszlo D, Labopin M et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675–3684.
Michallet M, Tanguy M, Socié G et al. Second allogeneic haemotopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle. Br J Haematol 2000; 108: 400–407.
Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461–466.
Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39–42.
Russell JA, Bowen T, Brown C et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant 1996; 18: 501–505.
Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304–313.
Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269–275.
Wagner JE, Vogelsang GB, Zehnbauer BA et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: 205–209.
Spinolo JA, Yau JC, Dicke KA et al. Second bone marrow transplants for relapsed leukemia. Cancer 1992; 69: 405–409.
Barrett CJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. Br J Haematol 1991; 79: 567–574.
Champlin RE, Ho WG, Lenarsky C et al. Successful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemia. Transplant Proc 1985; 17: 496–499.
Frassoni F, Barrett AJ, Grañena A et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the EBMT of 117 cases. Br J Haematol 1988; 70: 317–320.
Mehta J, Powles R, Treleaven J et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709–719.
Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 108: 400–407.
Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.
Shilling HG, McQueen KL, Cheng NW et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730–3740.
Falkenburg JH, van de Corput L, Marijt EW, Willemze R . Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003; 31: 743–751.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duus, J., Stiff, P., Choi, J. et al. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 35, 261–264 (2005). https://doi.org/10.1038/sj.bmt.1704761
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704761
Keywords
This article is cited by
-
Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation
Annals of Hematology (2017)
-
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
Bone Marrow Transplantation (2015)
-
Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT
International Journal of Hematology (2015)
-
Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation
Bone Marrow Transplantation (2014)
-
Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD
Bone Marrow Transplantation (2010)